Johnson & Johnson (JNJ) says it's close to settling a DoJ probe into the off-label marketing of its antipsychotic medication Risperdal. The settlement is expected to be one of the largest for a drug-marketing case, as JNJ and the government discuss a payment of $1.5B - $2B or higher. [View news story]
good grief! That is a bite in the shorts and no mistake.
Johnson & Johnson (JNJ) says it's close to settling a DoJ probe into the off-label marketing of its antipsychotic medication Risperdal. The settlement is expected to be one of the largest for a drug-marketing case, as JNJ and the government discuss a payment of $1.5B - $2B or higher. [View news story]